Adaptive Biotechnologies Corporation ADPT
Updated: 11 Aug 2026
No signal published yet
We already track Adaptive Biotechnologies and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Adaptive Biotechnologies Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Adaptive Biotechnologies free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On July 29, 2026, Adaptive Biotechnologies reported second-quarter 2026 financial results, with total revenue rising 22% year-over-year to $71.6 million driven by strong growth in its MRD segment. The company raised its full-year 2026 MRD revenue guidance to between $268 million and $278 million. Additionally, management outlined plans to strategically separate its Immune Medicine business from its profitable MRD diagnostic unit.
What Firelda Watch includes for Adaptive Biotechnologies Corporation
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Adaptive Biotechnologies Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Adaptive Biotechnologies free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more